Coronavirus Funding Opportunity Announcements

Released by the GCO 3/18-3/30/2020

- Coronavirus (3/30/20)
- Coronavirus (3/29/20)
- Coronavirus (3/27/20), issue # 2
- Coronavirus (3/27/20), issue # 1
- Coronavirus (3/26/20)
- Coronavirus (3/25/20)
- Coronavirus (3/22/20)
- Coronavirus (3/18/20)
Dear Research Community,

Below are COVID-19 funding opportunities from the funding opportunity database SPIN. Please note that some opportunities have rapidly approaching deadlines.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>078383</td>
<td>NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)</td>
<td>National Institutes of Health/DHHS</td>
<td>PA-19-052</td>
<td>07-May-2020</td>
<td>100,000 USD</td>
</tr>
<tr>
<td>078391</td>
<td>NIH Exploratory/Developmental Research Grant Program</td>
<td>National Institutes of Health/DHHS</td>
<td>PA-19-053</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
<tr>
<td>078398</td>
<td>NIH Research Project</td>
<td>National Institutes of Health/DHHS</td>
<td>PA-19-056</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td>087590</td>
<td>RFP -- AMENDMENT -- 2020 NIAID Omnibus Broad Agency Announcement</td>
<td>Department of Health &amp; Human Services</td>
<td>HHS-NIH-NIAID-BAA2020-1</td>
<td>09-Apr-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td>SPIN ID</td>
<td>Program Title</td>
<td>Sponsor Name</td>
<td>Sponsor Number</td>
<td>Deadline Date</td>
<td>Funding Amount</td>
</tr>
<tr>
<td>---------</td>
<td>---------------</td>
<td>--------------</td>
<td>----------------</td>
<td>---------------</td>
<td>----------------</td>
</tr>
<tr>
<td>078383</td>
<td>NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)</td>
<td>National Institutes of Health/DHHS</td>
<td>PA-19-052</td>
<td>07-May-2020</td>
<td>100,000 USD</td>
</tr>
<tr>
<td>078391</td>
<td>NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)</td>
<td>National Institutes of Health/DHHS</td>
<td>PA-19-053</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
</tbody>
</table>

Contact Name
Contact Telephone
Contact Email
Sponsor Website
Program URL

Deadline Dates (ALL)

Synopsis
The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).
The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

**Synopsis**

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).

**Synopsis**

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. This Broad Agency Announcement is soliciting proposals that possess the research and development (R&D) expertise necessary for successfully carrying out research toward meeting the program objectives of the Division of Microbiology and Infectious
The Research Areas included in this NIAID OMNIBUS BROAD AGENCY ANNOUNCEMENT No. HHS-NIH-NIAID-BAA2020-1, as well as the projected amounts of available funding, are discussed below. Dates for receipt of proposals will be identified separately for EACH Research Area within the solicitation.

Description: DIVISION OF ALLERGY, IMMUNOLOGY AND TRANSPLANTATION (DAIT), NIAID, NIH

Research Area Title: Development of Radiation/Nuclear Medical Countermeasures (MCMs) The objective of this Research Area is to advance the development of candidate medical countermeasures (MCM) to reduce mortality and/or major morbidities associated with exposure to radiation from a radiological or nuclear incident. This Research Area will advance lead candidate MCMs toward eventual FDA approval or licensure to mitigate or treat radiation-induced injuries and thereby improve survival following a radiological event. It is anticipated that candidate MCMs will enter the evaluation and development pathway at various stages, from early research to post marketing (for drugs or biologics that are already licensed or approved for other indications). NIAID estimates one or two cost-reimbursement, completion type contracts may be awarded for this Research Area for an average annual total cost (direct and indirect costs combined) of up to $2 million for a non-severable base and option periods. It is anticipated that the total cost for the award(s) may vary depending upon the scope of the project and the technical objectives of the award(s). The length of time for which funding is requested should be consistent with the nature and complexity of the proposed research. In no event shall the period of performance proposed by an offeror exceed 3 years.

DIVISION OF MICROBIOLOGY AND INFECTIOUS DISEASES (DMID), NIAID, NIH

Research Area Title: Advanced Development of Vaccine Candidates for Acute Flaccid Myelitis (AFM) Associated with Enterovirus D68 The objective of this Research Area is to support the development of a candidate vaccine for EV D68 associated AFM. The primary vaccine candidate requested is an inactivated EV D68 vaccine; however, other technologies to develop a non-replicating EV D68 vaccine will be considered (e.g., VLP). Proposed inactivated EV D68 vaccines most likely will require an adjuvant using either a single vaccine vial format or a combination two vial antigen plus adjuvant format that uses bedside mixing. The preference is to use adjuvants that minimize regulatory concerns and expedite vaccine development into a Phase I clinical trial. Solicited products are anticipated to include: Development of inactivated EV D68 vaccines through a Phase I clinical trial. The Phase 1 clinical trial start date is targeted for 2021 while interim data assessment and/or completion of the clinical trial with draft data assessment is targeted prior to Aug 2022. NIAID estimates that one or more awards may be issued for this Research Area for a total cost of up to $3 million for the non-severable base work across all contracts (direct and indirect costs combined). The total duration of a proposed contract should be consistent with the nature and complexity of the offeror’s proposed research. The total
performance period comprised of the base and any options proposed by an Offeror should not exceed five (5) years which includes stability studies. Research Area Title: Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases One objective of this Research Area is to develop vaccines to address antibiotic resistant gram-negative bacteria focusing on, but not limited to, Burkholderia spp., Pseudomonas aeruginosa, Francisella tularensis, Yersinia pestis, and E. coli. A second objective is to support development of vaccines for emerging viruses and pandemic preparedness that includes but is not limited to alphaviruses (for example Eastern Equine Encephalitis (EEE)) and bunyaviruses (for example Rift Valley Fever Virus (RVFV)). NIAID seeks to focus this BAA on pathogens that have not recently received funding from NIAID, other agencies, or organizations. As a result, NIAID will exclude – specifically for this BAA - the following pathogens: Filoviruses, Lassa, MERS, Chikungunya, Zika and Nipah. Solicited products are anticipated to include: Lead candidate vaccines that have sufficient proof of concept data and/or clinical data to support vaccine development through manufacturing, toxicology testing, and testing in phase I/II clinical trials. NIAID estimates that three or more awards may be issued across this Research Area and the next Research Area title “Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases” for a total cost of up to $11.5 million for the non-severable base work across all contracts (direct and indirect costs combined). The total duration of a proposed contract should be consistent with the nature and complexity of the offeror’s proposed research. The total performance period comprised of the base and any options proposed by an Offeror should not exceed five (5) years. Research Area Title: Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases The objective of this Research Area is the development of promising new therapeutics to address infections caused by NIAID Category A, B, and C priority pathogens. For the purposes of this solicitation, therapeutic activity is defined as the cure or mitigation of disease, preferably, once signs and symptoms of infection are evident. For the purposes of this solicitation, a therapeutic candidate is either a lead series, lead, or product candidate, and is either a drug (synthetic or natural product) or a biological product (e.g. monoclonal antibodies, recombinant proteins). This Research Area support lead optimization, pre-clinical (IND enabling) and clinical trials that include Phase 1 and Phase 2 studies. Solicited products are anticipated to include: Therapeutic lead series/lead/product candidate must address infections caused by one or more pathogens listed among NIAID Category A, B, and C priority pathogens, NIAID estimates that three or more awards may be issued across this Research Area and the preceding Research Area title “Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases” for a total cost of up to $11.5 million for the non-severable base work across all contracts (direct and indirect costs combined).
contract should be consistent with the nature and complexity of the offeror’s proposed research. The total performance period comprised of the base and any options proposed by an Offeror should not exceed five (5) years. Research Area Title: Advanced Development of Diagnostics for Biothreats and Emerging Infectious Diseases The objective of this Research Area is to advance the development of novel, rapid sample-to-answer candidate diagnostic products that will address biodefense and pandemic preparedness. Initial proof-of-concept demonstration that diagnostic method can detect a biological component (e.g., pathogen, protein, nucleic acid, etc), preferable in a relevant clinical matrix (e.g., blood, urine, swab, etc) is required for preliminary data. Solicited products are anticipated to include: Early through late-stage diagnostics to address biodefense and pandemic preparedness. Diagnostic must detect one of the following agents: Bacillus anthracis and must phenotypically determine its antibiotic susceptibility Yersinia pestis and must phenotypically determine its antibiotic susceptibility Francisella tularensis and must phenotypically determine its antibiotic susceptibility Burkholderia sp. and must phenotypically determine its antibiotic susceptibility Botulinum toxin and must identify and distinguish relevant serotypes Lassa virus Nipah virus Rift Valley Fever virus Enterovirus D68 virus Zika virus Candida auris Coccidioides sp. NIAID estimates that one or more awards may be issued for this Research Area for a total cost of up to $2 million for the non-severable base work across all contracts (direct and indirect costs combined). The total duration of a proposed contract should be consistent with the nature and complexity of the offeror’s proposed research. The total performance period comprised of the base and any options proposed by an Offeror should not exceed five (5) years. The Omnibus BAA is governed by Federal Acquisition Regulation (FAR) 6.102(d)(2) and FAR 35.016, as well as the NIH Policy Manual, Manual Chapter 6035, Broad Agency Announcements. A BAA may be used as a solicitation mechanism for basic and applied research directed toward advancing the state-of-the-art or increasing knowledge or understanding and that part of development not related to the development of a specific system or hardware procurement. BAAs are general in nature, identifying areas of research interest, and shall only be used when meaningful proposals with varying technical/scientific approaches can be reasonably anticipated. Offers submitted in response to this BAA will be required to present separate detailed technical and business proposals designed to meet the Technical Objectives described for each Research Area proposed. The Statement of Work (SOW), including the specific technical requirements and performance specifications, shall be developed and proposed by the Offeror, not the Government. Proposals received in response to this BAA are NOT evaluated against each other since they are not submitted in accordance with a common SOW issued by the Government. Instead, Research and Technical Objectives will be provided in the BAA that describe individual Research Areas in which the Government is interested. Proposals received in response to the BAA will be
evaluated in accordance with the Evaluation Factors for Award specified in the announcement. The Government reserves the right to conduct discussions with all, some, one, or none of the proposals received in response to this BAA. If discussions are conducted, the Government reserves the right to suggest modifying, adding or deleting milestones, decision points, research plans, processes, schedules, budget or product. The Government also reserves the right to make awards without discussions. Additionally, the Government reserves the right to accept proposals in their entirety or to select only portions of proposals for award. Multiple awards are anticipated. Selection for award under this BAA will be based upon the evaluation factors, importance to the agency programs, and the availability of funds. Any responsible offeror may submit a proposal which shall be considered by the Agency. This BAA will be available electronically on or about December 31, 2019 and may be accessed through Beta Sam: https://beta.sam.gov/. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted. For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by facsimile or e-mail is not acceptable. For directions on using eCPS, go to the website: https://ecps.nih.gov and then click on "How to Submit."

091236 COVID-19 Relief Fund  
Robin Hood Foundation  
Continuous Submission  
45,000 USD

Contact Name
Contact Telephone 212-227-6601
Contact Email grants@robinhood.org
Sponsor Website Link to sponsor website
Program URL Link to program URL
Deadline Dates (ALL)

Synopsis
Robin Hood anticipates making grants to 501(c)(3) organizations in New York City that are well-positioned to serve low-income communities. The initial grants, expected to last three months in duration, will average $45,000.

091244 NEA Research Labs, FY2021
National Endowment for the Arts/National Fndn. on the Arts & Humanities
2020NEA01ORALABS
13- Apr-2020
150,000 USD

Contact Name
Contact Telephone 202-682-5654
Contact Email iyengars@arts.gov
Sponsor Website
Program URL Link to program URL
Deadline Dates (ALL) 13-Apr-2020 , 23-Apr-2020

NEA's five-year research agenda aims to build public knowledge about the arts’ contributions to individuals and society. Through the NEA Research Labs (“Research Labs”), we seek to extend this agenda and its impact by cultivating a series of transdisciplinary research partnerships, grounded in the social and behavioral sciences, to produce and report empirical insights about the arts for the benefit of arts and non-arts sectors alike.

Visit the Research Portal Getting Started page and enter email address under Research Listserv to update your subscription preferences at any time within the MSHS firewall.

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.
This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.
Dear Research Community,

Below are COVID-19 funding opportunities recently released by the NIH.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been emailed are posted on GCO’s Funding Opportunities page.

The Grants and Contracts Office

From: Table of Contents for the NIH Guide for Grants & Contracts On Behalf Of Guide TOC
Sent: Friday, March 27, 2020 3:00 PM
To: NIHTOC-L@LIST.NIH.GOV
Subject: NIH Funding Opportunities and Notices for 03-27-2020 (The NIH Guide TOC)
Weekly NIH Funding Opportunities and Notices for March 27, 2020

General Notices

- **Notice of Early Expiration of Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV), NOT-AI-20-030**
  (NOT-AI-20-040)
  National Institute of Allergy and Infectious Diseases
  National Institute of General Medical Sciences

  (NOT-HS-20-008)
  Agency for Healthcare Research and Quality

Notice of Changes to Funding Opportunities

- **Notice of NIBIB's Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"**
  (NOT-EB-20-004)
  National Institute of Biomedical Imaging and Bioengineering

Notices of Special Interest

- **Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)**
  (NOT-AI-20-031)
  National Institute of Allergy and Infectious Diseases

- **Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)**
  (NOT-AI-20-034)
  National Institute of Allergy and Infectious Diseases

- **Notice of Special Interest: NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)**
  (NOT-ES-20-014)
  National Institute of Environmental Health Sciences

- **Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2**
  (NOT-GM-20-025)
  National Institute of General Medical Sciences

- **Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)**
NIH Funding Opportunities now available in RSS (Really Simple News Syndication) format - see https://grants.nih.gov/grants/guide/rss_info.htm for details.

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE. This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

Visit the Research Portal Getting Started page and enter email address under Research Listserv to update your subscription preferences at any time within the MSHS firewall.
Dear Research Community,

Below is a COVID-19 funding opportunity recently released by the NIH.

**Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional) (PA-20-135)**

The Grants and Contracts Office
Dear Research Community,

Below are COVID-19 funding opportunities from the funding opportunity database SPIN. Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been emailed are posted on GCO's Funding Opportunities page.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Opportunity Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>091059</td>
<td>Competitive Fund for Peace and Recovery Innovations for Poverty Action</td>
<td>None</td>
<td>None posted</td>
<td>Not Available</td>
<td></td>
</tr>
<tr>
<td>074562</td>
<td>Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory Mechanisms (R21 Clinical Trial Not Allowed) Enhancing Global Health Security: Expanding Efforts</td>
<td>National Institute of Allergy and Infectious Diseases/NIH/DHHS</td>
<td>PAR-18-781</td>
<td>09-Sep-2020</td>
<td>275,000.00 USD</td>
</tr>
<tr>
<td>Code</td>
<td>Title</td>
<td>Grantee</td>
<td>RFA Number</td>
<td>Application Due Date</td>
<td>Amount</td>
</tr>
<tr>
<td>-------</td>
<td>------------------------------------------------------------------------</td>
<td>------------------------------</td>
<td>-------------------</td>
<td>-----------------------</td>
<td>------------</td>
</tr>
<tr>
<td>089828</td>
<td><strong>and Strategies to Protect and Improve Public Health Globally</strong></td>
<td>Center for Global Health/CDC/DHHS</td>
<td>RFA-GH20-2110</td>
<td>27-Apr-2020</td>
<td>75,000,000.00 USD</td>
</tr>
<tr>
<td>089982</td>
<td><strong>Building Capacity for National Public Health Institutes</strong></td>
<td>Center for Global Health/CDC/DHHS</td>
<td>RFA-GH20-2107</td>
<td>04-May-2020</td>
<td>15,000,000.00 USD</td>
</tr>
<tr>
<td>089996</td>
<td><strong>Global Health Security Partnerships: Expanding and Improving Public Health Laboratory Strategies and Systems.</strong></td>
<td>Center for Global Health/CDC/DHHS</td>
<td>RFA-GH20-2109</td>
<td>04-May-2020</td>
<td>25,000,000.00 USD</td>
</tr>
<tr>
<td>089809</td>
<td><strong>Strengthening Global Field Epidemiology Training Program (FETP) Network</strong></td>
<td>Center for Global Health/CDC/DHHS</td>
<td>RFA-GH20-2108</td>
<td>27-Apr-2020</td>
<td>105,000,000.00 USD</td>
</tr>
</tbody>
</table>

SMARTS™ funding alerts are a service of InfoEd Global's SPIN™ funding opportunities.
Dear Research Community,

Below are COVID-19 funding opportunities from the funding opportunity database SPIN. Please note that some opportunities have rapidly approaching deadlines. Previously posted COVID-19 funding opportunities are posted on GCO's Funding Opportunities page.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Opportunity Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>089235</td>
<td>Epidemic Preparedness: COVID-19 Funding Call</td>
<td>Wellcome Trust</td>
<td>Continuous Submission</td>
<td>Not Specified</td>
<td></td>
</tr>
<tr>
<td>090791</td>
<td>C19 – Work From Home Cybersecurity Grant</td>
<td>Campus Consortium</td>
<td>03-Apr-2020</td>
<td>100,000.00 USD</td>
<td></td>
</tr>
<tr>
<td>090798</td>
<td>Coronavirus Local Response Initiative</td>
<td>Bloomberg Philanthropies</td>
<td>Continuous Submission</td>
<td>Not Specified</td>
<td></td>
</tr>
<tr>
<td>090799</td>
<td>Health Security and Pandemics Challenge</td>
<td>MIT Solve</td>
<td>18-Jun-2020</td>
<td>10,000.00 USD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NYC COVID-19 Response &amp; Impact Fund -- Human Services</td>
<td>New York Community Trust</td>
<td>30-May-2020</td>
<td>250,000.00 USD</td>
<td></td>
</tr>
<tr>
<td>090817</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>090918</td>
<td>Brooklyn COVID-19 Response Fund</td>
<td>Brooklyn Community Foundation</td>
<td>Continuous Submission</td>
<td>10,000.00 USD</td>
<td></td>
</tr>
<tr>
<td>091046</td>
<td>Emergency Fund for the COVID19 Pandemic</td>
<td>Staunton Farm Foundation</td>
<td>Continuous Submission</td>
<td>Not Specified</td>
<td></td>
</tr>
</tbody>
</table>

SMARTS™ funding alerts are a service of InfoEd Global’s SPIN™ funding opportunities.
Dear Research Community,

Below are COVID-19 funding opportunities from the funding opportunity database SPIN. Please note that some opportunities have rapidly approaching deadlines.

In addition, please review the [SPIN Getting Started Instructions](https://professional.heart.org/professional/ResearchPrograms/UCM_505867_AHA-Rapid-Response-Grant-COVID-19-and-its-Cardiovascular-Impact.jsp) for information about beginning your individual search.

The Grants and Contracts Office

<table>
<thead>
<tr>
<th>SPIN Opportunity ID</th>
<th>Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>090954</td>
<td>AHA Rapid Response Grant -- COVID-19 and Its Cardiovascular Impact</td>
<td>American Heart Association</td>
<td>06-Apr-2020</td>
<td>100,000.00 USD</td>
<td></td>
</tr>
</tbody>
</table>

There is an urgent need to better understand the pathobiology and the clinical implications of the viral infection that leads to the morbidity and mortality seen...
with COVID-19. To address this need, the American Heart Association (AHA) invites cardiovascular-focused applications that will contribute to understanding the cardiovascular and cerebrovascular pathogenesis, diagnosis, prevention, clinical manifestations, clinical management (including critical care management) and social behaviors which can lead to dissemination, containment, and complications of COVID-19.

To ensure rapid dissemination of results to the medical and research communities, one grant recipient will be selected to establish the COVID-19 Coordinating Center. This center will coordinate communication among the awardees, help establish collaborations where appropriate, receive results from all awardees and serve to coordinate dissemination of all findings resulting from this mechanism.

LifeArc has made available an initial £10M for the identification of therapeutics that can be rapidly deployed to treat COVID-19. The aim is to run trials in patients during the current epidemic. It is anticipated that applications will be for funding to repurpose one or more drugs
that are generic, already licensed, or are in late stage development for another indication.

<table>
<thead>
<tr>
<th>Medical CBRN Defense Consortium (MCDC) Other Transaction Agreement (OTA) Request for Information (RFI) – CoV Pandemic Response</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Email</strong></td>
</tr>
<tr>
<td><strong>Sponsor Website</strong></td>
</tr>
<tr>
<td><strong>Program URL</strong></td>
</tr>
<tr>
<td><strong>Deadline Dates (ALL)</strong></td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RFP -- Centers for Disease Control COVID-19 Broad Agency Announcement</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Name</strong></td>
</tr>
<tr>
<td><strong>Contact Email</strong></td>
</tr>
<tr>
<td><strong>Program URL</strong></td>
</tr>
<tr>
<td><strong>Deadline Dates (ALL)</strong></td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>C19 – Artificial Intelligence for Rapid Response Grant</th>
<th>Campus Consortium</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Telephone</strong></td>
<td>216-589-9626</td>
</tr>
<tr>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:grantapplication@campusconsortium.org">grantapplication@campusconsortium.org</a></td>
</tr>
<tr>
<td><strong>Sponsor Website</strong></td>
<td><a href="https://www.campusconsortium.org/">https://www.campusconsortium.org/</a></td>
</tr>
<tr>
<td><strong>Program URL</strong></td>
<td><a href="https://www.campusconsortium.org/philanthropy/grant-programs/c19-artificial-intelligence-for-rapid-response-grant/">https://www.campusconsortium.org/philanthropy/grant-programs/c19-artificial-intelligence-for-rapid-response-grant/</a></td>
</tr>
<tr>
<td><strong>Deadline Dates (ALL)</strong></td>
<td>03-Apr-2020</td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>The purpose of this special notice is to obtain information via White Papers from both MCDC members and other interested industry/academia partners in response to the novel Coronavirus (2019-nCoV) pandemic in the United States (U.S.).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>C19 – Artificial Intelligence for Rapid Response Grant</th>
<th>Campus Consortium</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Telephone</strong></td>
<td>216-589-9626</td>
</tr>
<tr>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:grantapplication@campusconsortium.org">grantapplication@campusconsortium.org</a></td>
</tr>
<tr>
<td><strong>Sponsor Website</strong></td>
<td><a href="https://www.campusconsortium.org/">https://www.campusconsortium.org/</a></td>
</tr>
<tr>
<td><strong>Program URL</strong></td>
<td><a href="https://www.campusconsortium.org/philanthropy/grant-programs/c19-artificial-intelligence-for-rapid-response-grant/">https://www.campusconsortium.org/philanthropy/grant-programs/c19-artificial-intelligence-for-rapid-response-grant/</a></td>
</tr>
<tr>
<td><strong>Deadline Dates (ALL)</strong></td>
<td>03-Apr-2020</td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>The purpose of this special notice is to obtain information via White Papers from both MCDC members and other interested industry/academia partners in response to the novel Coronavirus (2019-nCoV) pandemic in the United States (U.S.).</td>
</tr>
</tbody>
</table>
Due to the recent C19 pandemic, the Campus Consortium has partnered with Unifyed to provide the technology platform and services for the Artificial Intelligence for Rapid Response Grant. The Artificial Intelligence for Rapid Response Grant is designed to help schools address the high call and query volume they are receiving by providing Unifyed’s Yoda Rapid Response, an AI-enabled chat service that can help answer FAQ and provide self-help assistance to students, faculty and staff. The Artificial Intelligence for Rapid Response Grant will provide awarded institutions with the requisite licenses and services to a comprehensive Artificial Intelligence solution. Following the Campus Consortium’s due diligence process, grant recipients may receive up to $50,000 in software licenses, support and implementation services for a term of up to five years.

RFA-AI-20-028 -- Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed)

National Institute of Allergy and Infectious Diseases/NIAID/DHHS 028 30-May-2020 [Optional] [LOI/Pre-App] 3,750,000.00 USD

Contact Name Michael R. Schaefer, Ph.D.
Contact Telephone 240-627-3364
Contact Email mschaefer@niaid.nih.gov

The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.

SMARTSTM funding alerts are a service of InfoEd Global’s SPINSTM funding opportunities.
Dear Research Community,

Below are COVID-19 funding opportunities. The first set are from the NIH Guide of Funding Opportunities and Notices for 03-20-2020 (The NIH Guide TOC) and the second are alerts from the funding opportunity database SPIN. Please review the SPIN Getting Started Instructions for information about beginning your search.

The Grants and Contracts Office

**Weekly NIH Funding Opportunities and Notices for March 20, 2020**

- [Notice of NIBIB's Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"
  (NOT-EB-20-003)](NOT-EB-20-003)
  National Institute of Biomedical Imaging and Bioengineering

- [Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
  (NOT-DA-20-047)](NOT-DA-20-047)
  National Institute on Drug Abuse

- [Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
  (NOT-HL-20-757)](NOT-HL-20-757)
  National Heart, Lung, and Blood Institute
<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Opportunity Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>077858</td>
<td>Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)</td>
<td>National Institutes of Health/DHHS</td>
<td>PA-18-935</td>
<td>None posted</td>
<td>Not Available</td>
</tr>
<tr>
<td>090761</td>
<td>Dear Colleague Letter--Coronavirus Disease 2019 (COVID-19)</td>
<td>None</td>
<td>None</td>
<td>Not posted</td>
<td>Available</td>
</tr>
<tr>
<td>071528</td>
<td>Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)</td>
<td>National Institutes of Health/DHHS</td>
<td>PA-18-591</td>
<td>None posted</td>
<td>Not Available</td>
</tr>
</tbody>
</table>

**Synopsis**

The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA.

The emergence and spread of the new respiratory Corona virus Disease 2019 (COVID-19), which was declared a Public Health Emergency in the United States on January 31, 2020, has catalyzed significant activity by Federal, state, and local governments; the healthcare community; residents across the United States; and people around the world. The National Biodefense Strategy is the nation's plan for ensuring that the country is prepared for, responding to, and recovering from health incidents such as these. As a partner in the Strategy, the Department of Energy (DOE) contributes science and technology to support these efforts. This is not the first emerging infectious disease event that the world will face, nor will it be the last. DOE is soliciting ideas about how DOE and the National Labs might contribute resources to help address COVID-19 through science and technology efforts and collaborations.
National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC's web site to ensure they meet the IC's requirements.

SMARTSTM funding alerts are a service of InfoEd Global's SPINTM funding opportunities.
Below is a summary of COVID-19 related funding opportunities followed by more detailed information for each.

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>088971</td>
<td>RFP -- AMENDMENT--Office of Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)</td>
<td>Department of Health &amp; Human Services BARDABAA-18-100-SOL</td>
<td>31-Oct-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td>088719</td>
<td>RFP -- AMENDMENT --- BARDA’s Division of Research, Innovation &amp; Ventures (DRIVE) Easy Broad Agency Announcement</td>
<td>Department of Health &amp; Human Services BAA-20-100-SOL-0002</td>
<td>03-Feb-2023</td>
<td>Not Specified</td>
</tr>
<tr>
<td>090432</td>
<td>RFP -- Prototype Development to Combat Novel Coronavirus Disease COVID-19</td>
<td>Department of the Army MTEC-Presolicitation-COVID-19</td>
<td>15-Apr-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td>090388</td>
<td>Travel and Subsistence Funding to Support LMIC Engagement During the COVID-19 Outbreak</td>
<td>National Institute for Health Research Continuous Submission</td>
<td></td>
<td>Not Specified</td>
</tr>
<tr>
<td>082661</td>
<td>Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) (Defunct)</td>
<td>National Institute of Allergy and Infectious Diseases/NIH/DHHS PA-19-272</td>
<td>06-Apr-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td>090387</td>
<td>RFA-AI-20-028 -- Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed)</td>
<td>National Institute of Allergy and Infectious Diseases/NIH/DHHS RFA-AI-20-028 [Optional][LOI/Pre-App]</td>
<td>30-May-2020</td>
<td>3,750,000 USD</td>
</tr>
<tr>
<td>077858</td>
<td>Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)</td>
<td>National Institutes of Health/DHHS PA-18-935</td>
<td>Continuous Submission</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>
Summary – Other Federal Funding Opportunities


   Required white papers are due 3:00 PM EST on March 25, 2020

2. **NIH Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)**

   Instructions for the Competitive Revisions are listed in the NOSI, and the expiration date for this opportunity is February 6, 2021 by 5:00 PM local time of the applicant organization.

3. **NSF Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19) and RAPID Response**

   Requests for RAPID proposals may be for up to $200K and up to one year in duration.
## Detailed Information on COVID-19 Funding Opportunities

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>088971</td>
<td>RFP -- AMENDMENT -- Office of Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)</td>
<td>Department of Health &amp; Human Services</td>
<td>BARDABAA-18-100-SOL</td>
<td>31-Oct-2020</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>

**Contact Name**: Carl Newman  
**Contact Telephone**: carl.newman@hhs.gov  
**Contact Email**: oke.obi@hhs.gov  
**Sponsor Website**

**Program URL**: Link to program URL  
**Deadline Dates (ALL)**: 31-Oct-2020  

**Synopsis**: The latest BARDA BAA is amendment 12 posted on February 10, 2020 which incorporates changes to AOI 7-Diagnostics. BARDA is now accepting submissions to AOI 7.7 for development of assays for coronaviruses. Due to an overwhelming response to Area of Interest 7, BARDA is temporarily closing AOI's; Innovations (7.1), biothreats (7.2), antibiotic resistance (7.3) and influenza (7.6). AOI's radiation exposure/biodosimetry (7.4), and chemical threat exposure (7.5) remain closed. The final white paper submission deadline is October 31, 2020. The final full proposal submission deadline is October 31, 2020 or as specified in the invitation letter. Additional beta.sam.gov information Notice Id cf2836e2f4b3406f9f492230ece030c7  
**Source**: https://beta.sam.gov/opp/cf2836e2f4b3406f9f492230ece030c7/view

| 088719  | RFP -- AMENDMENT -- BARDA's Division of Research, Innovation & Ventures (DRIVE) Easy Broad Agency Announcement | Department of Health & Human Services | BAA-20-100-SOL-0002 | 03-Feb-2023 | Not Specified |

**Contact Name**: Troy Francis - Contracting Officer (Team Lead), DRIVE  
**Contact Telephone**: troy.francis@hhs.gov  
**Contact Email**: troy.francis@hhs.gov  
**Sponsor Website**
**Synopsis**

Please see Special Instructions 001 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions, BARDA is temporarily suspending AOIs 1-3 as part of its EZ-BAA (BAA-20-100-SOL-0002), but is pleased to announce that it is now accepting abstract submissions for AOI #4: 2019-nCoV. See attachment(s). This Easy Broad Agency Announcement (EZ-BAA) sets forth areas of interest (AOIs) for the Division of Research, Innovation, and Ventures (DRIVE) in the Office of Biomedical Advanced Research and Development Authority (BARDA), issued under paragraph 6.102(d)(2)(i) of the Federal Acquisition Regulation (FAR). Abstract submissions selected for award are considered to be the result of full and open competition and in full compliance with 41 U.S.C. § 3301. Additional beta.sam.gov information Notice Id: 17e5a57c31674b96b996bfc99cc6cc54

Source: https://beta.sam.gov/opp/17e5a57c31674b96b996bfc99cc6cc54/view

Note: This link might not be valid after archive date below. Archive Date: 2/18/2023

---

<table>
<thead>
<tr>
<th>Code</th>
<th>Title</th>
<th>Sponsor</th>
<th>Deadline Dates (ALL)</th>
<th>Program URL</th>
<th>Contact Name</th>
<th>Contact Telephone</th>
<th>Contact Email</th>
<th>Sponsor Website</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>090432</td>
<td>RFP -- Prototype Development to Combat Novel Coronavirus Disease COVID-19</td>
<td>Department of the Army</td>
<td>15-Apr-2020</td>
<td>Not Specified</td>
<td>Randall Fernanders</td>
<td>843-760-3378</td>
<td><a href="mailto:randall.fernanders@ati.org">randall.fernanders@ati.org</a></td>
<td>Link to sponsor website</td>
<td>The Medical Technology Enterprise Consortium (MTEC) is excited to post this pre-announcement for a potential Request for Project Proposals (RPP) focused on the development of prototypes aimed to combat the coronavirus (COVID-19). *CAUTION: All information contained in this pre-announcement has not been formally approved by the Government, and represents MTEC’s interpretation of the situation at this time. All information is subject to change. PROGRAM BACKGROUND: In light of the magnitude and potential threat that the coronavirus (COVID-19) poses to our military’s health and readiness, the Government seeks to rapidly accelerate the inquiry, testing, and fielding of</td>
</tr>
</tbody>
</table>
new 21st century capabilities, employing novel technologies and approaches to the
detection of exposure, prevention, containment and treatment of COVID-19 and future
emerging threats. SOLUTION REQUIREMENTS: This pre-announcement has been developed
by MTEC to provide notice for the possibility of one or more upcoming RPPs focused on
combating COVID-19. This notice may also help the membership form appropriate
partnerships/teaming relationships so that they are poised to respond to the full
requirements described in potential upcoming RPPs. CAUTION: These solution
requirements have not been formally established by the Government, and are solely
MTEC’s interpretation of the critical needs of the U.S. military. MTEC believes that an
emphasis will be placed on technologies that can be deployed as soon as possible but no
later than 31 December 2020. In support of this, MTEC has identified the following
potential areas of interest: Point-of-care diagnostic that provides rapid and accurate
determination on exposure to COVID-19. Prophylactic(s)/Therapeutic(s) that can prevent
and/or treat in a rapid manner (few hours to 2 days) potentially in a non-hospital
environment. Repurposing FDA-approved drugs/biologics for prevention/treatment of
COVID-19 or testing of drugs/biologics that have already demonstrated safety in humans
for the prevention/treatment of COVID-19 are preferred. Disease predictive modeling that
provides early warning through data capture from several different streams of data to
include social media and artificial intelligence (AI) parameter decision tools that would
provide actionable information to medical service providers and command structures.
Patient monitoring, tracking, and management system for in-home or non-hospital
environment patient tele-health services to include interface into the Cerner electronic
health record. POTENTIAL FUNDING: Although there is no specific funding commitment by
the U.S. Government at this time, MTEC believes that there may be tens of millions of
dollars available for combating COVID-19 programs with a likelihood of follow-on funding.
ACQUISITION APPROACH: The MTEC will implement the “Enhanced White Paper”
contracting methodology for this potential upcoming RPP(s), which will be an accelerated
approach to award. Because of the nature and urgency of the program’s requirements, this
streamlined approach is anticipated to be a better means to highlight company
methodologies and skills required to address the technical and transition requirements.
The Enhanced White Paper process requires extremely quick turnaround times by Offerors.
Once the RPP is released, Offerors will be required to submit their Enhanced White Papers
within two weeks. Enhanced White Papers will include an abbreviated technical approach,
detailed statement of work, and an estimate of cost. All Enhanced White Papers will be
provided to the Government for scientific and programmatic relevance evaluation. Upon
review of the Enhanced White Papers, several Offerors may be invited for informal
discussions with the Government. Offerors who are recommended for award will be
required to submit a full cost proposal. MTEC anticipates that awards will be issued within
4-6 weeks of the RPP release date. Please pay special attention to the upcoming RPP
instructions because of the changes that will be made to accommodate the expedited
solicitation to award timeframes. The upcoming RPP(s) will be posted to the MTEC website
(mtec-sc.org) and a notice will be posted on www.beta.SAM.gov to notify interested
parties. Contingent upon approval from the Government, the upcoming RPP(s) is expected
to be released within the next few weeks and will have an extremely short preparation
period (approximately 14 days). Due to the critical and urgent nature of the technical topic
area, MTEC membership is NOT required for the submission of an enhanced white paper in
response to this upcoming MTEC RPP. However, membership will be required for Offerors
recommended for award. To join MTEC, please visit http://mtec-sc.org/how-to-join/. MTEC
MEMBER TEAMING: While teaming is not required for this effort, Offerors are encouraged
to consider teaming during the proposal preparation period (prior to proposal submission)
if they cannot address the full scope of technical requirements of the RPP or otherwise
believe a team may be beneficial to the Government. MTEC members are encouraged to
use the MTEC Database Collaboration Tool to help identify potential teaming partners
among other MTEC members. The Database Collaboration Tool provides a quick and easy
way to search the membership for specific technology capabilities, collaboration interest,
core business areas/focus, R&D highlights/projects, and technical expertise. Contact
information for each organization is provided as part of the member profile in the
collaboration database tool to foster follow-up conversations between members as
needed. The Collaboration Database Tool can be accessed via the “MTEC Profiles Site” tab
on the MTEC members-only website. MTEC: The MTEC mission is to assist the U.S. Army
Medical Research and Development Command (USAMRDC) by providing cutting-edge
technologies and supporting life cycle management to transition medical solutions to
industry that protect, treat, and optimize Warfighters’ health and performance across the
full spectrum of military operations. MTEC is a biomedical technology consortium
collaborating with multiple government agencies under a 10-year renewable Other
Transaction Agreement (OTA), Agreement No. W81XWH-15-9-0001, with the U.S. Army
Medical Research Acquisition Activity (USAMRAA). MTEC is currently recruiting a broad
and diverse membership that includes representatives from large businesses, small businesses,
“nontraditional” defense contractors, academic research institutions and not-for-profit
organizations. POINTS OF CONTACT: For inquiries regarding this pre-announcement, please
direct your correspondence to the following contacts: Technical and membership
questions – Dr. Lauren Palestrini, MTEC Director of Research,
lauren.palestrini@officer.mtec-sc.org Programmatic questions – Ms. Kathy Zolman, MTEC
Director of Program Operations, kathy.zolman@ati.org MTEC Member Collaboration
Database Tool – Ms. Melissa Sanchez, MTEC Program Administrator,
melissa.sanchez@ati.org Additional beta.sam.gov information Notice
Id 53badf9fb02349e78839a541495efc6a
Source https://beta.sam.gov/opp/53badf9fb02349e78839a541495efc6a/view Note:
This link might not be valid after archive date below. Archive Date 4/30/2020

<table>
<thead>
<tr>
<th>090388</th>
<th>Travel and Subsistence Funding to Support LMIC Engagement During the COVID-19 Outbreak</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Institute for Health Research</td>
<td>Continuous Submission</td>
</tr>
</tbody>
</table>

Contact Name | ccf-nCoV@nihr.ac.uk |
Contact Telephone | |
Contact Email | |
Sponsor Website | Link to sponsor website |
Program URL | Link to program URL |
Deadline Dates (ALL) |
The awards will provide travel and subsistence funding to appropriately qualified public health professionals, clinicians and academics who wish to offer science and technical advice to support the immediate response to COVID-19 in low and middle-income countries. The awards are open to applicants who have a substantive position at a UK higher education institution or research organisation.

**Synopsis**

**Small Business Innovation Research Grant Applications**

<table>
<thead>
<tr>
<th>Grant Type</th>
<th>Organization</th>
<th>FOA Number</th>
<th>Application Deadline</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>PA-19-272</td>
<td>National Institute of Allergy and Infectious Diseases/NIH/DHHS</td>
<td>06-Apr-2020</td>
<td>Not Specified</td>
<td></td>
</tr>
</tbody>
</table>

**Contact Name:** Dr. Natalia Kruchinin  
**Contact Telephone:** 240-669-2919  
**Contact Email:** kruchininn@niaid.nih.gov  
**Sponsor Website:** [Link to sponsor website](#)  
**Program URL:** [Link to program URL](#)

**Synopsis**

This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH, CDC, and FDA awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials.

**Contact Name:** Michael R. Schaefer, Ph.D.  
**Contact Telephone:** 240-627-3364  
**Contact Email:** mschaef@niaid.nih.gov  
**Sponsor Website:** [Link to sponsor website](#)  
**Program URL:** [Link to program URL](#)

**Deadline Dates (ALL):**  
- 06-Apr-2020
- 30-May-2020 [Optional][LOI/Pre-App], 29-Jun-2020
### Funding Opportunity Announcement (FOA)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.

**Contact Name:** Mahua Mukhopadhyay, PhD  
**Contact Telephone:** 301-435-6886  
**Contact Email:** mukhopam@mail.nih.gov  
**Sponsor Website:** [Link to program URL](#)  

### Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions

The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences for undergraduate students and enhancing the research environment at these applicant institutions. Eligible institutions must award baccalaureate science degrees and have received less than 6 million dollars per year of NIH support (total costs) in 4 of the last 7 fiscal years. This funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. Minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.

**Contact Name:**  
**Contact Telephone:**  
**Contact Email:**  
**Sponsor Website:**  
**Program URL:** [Link to program URL](#)  
**Deadline Dates (ALL):**

<table>
<thead>
<tr>
<th>Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)</th>
<th>National Institutes of Health/DHHS</th>
<th>PA-18-935</th>
<th>Continuous Submission</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>077858</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific
public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA.

<table>
<thead>
<tr>
<th>071528</th>
<th><strong>Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)</strong></th>
<th>National Institutes of Health/DHHS</th>
<th>PA-18-591</th>
<th>Continuous Submission</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td></td>
<td></td>
<td></td>
<td><a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td></td>
<td></td>
<td></td>
<td><a href="mailto:epidemics@wellcome.ac.uk">epidemics@wellcome.ac.uk</a></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td>Link to sponsor website</td>
<td></td>
</tr>
</tbody>
</table>

Synopsis

National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC's web site to ensure they meet the IC's requirements.
This call aims to strengthen the evidence base to better prevent and control coronavirus (COVID-19) epidemics and to increase research and response capacity. It’s part of an existing partnership between Wellcome and the UK Department for International Development (DFID) through the Joint Initiative on Research in Epidemic Preparedness and Response to help low- and middle-income countries prepare for and tackle epidemics.

Detailed – Other Federal Funding Opportunities

   - Areas of Interest (see attached RFA for additional information):
     1. Surveillance, natural history and household transmission of SARS CoV-2
     2. Diagnostics development and novel technology development and evaluation to improve diagnostic testing capabilities for COVID-19 detection
     3. Immune response and transmission dynamics for SARS CoV-2
     4. Host infection dynamics for SARS CoV-2
     5. Prospective Cohorts to Assess COVID-19 and Other Respiratory Diseases
   - Interested applicants should consider emailing the initial point of contact listed in the RFA (starting on page 4)
   - Required white papers are due **3:00 PM EST on March 25, 2020**, and can be no more than **4 pages in length** (include cover page, appendices, etc.)

2. **NIH Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)**
   - NIAID and NIGMS are issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (2019-nCoV). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV.
   - NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens.
   - NIAID and NIGMS are therefore offering Competitive Revisions to active grants addressing research objectives described in the NOSI.
   - Instructions for the Competitive Revisions are listed in the NOSI, and the expiration date for this opportunity is **February 6, 2021 by 5:00 PM** local time of the applicant organization.

   - NSF is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.
• NSF encourages the research community to respond to this challenge through **existing funding opportunities**.

• In addition, NSF invites researchers to use the **Rapid Response Research (RAPID) funding mechanism**, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Requests for RAPID proposals may be for up to $200K and up to one year in duration. Well-justified proposals that exceed these limits may be entertained. All questions should be directed either to a program officer managing an NSF program with which the research would be aligned or to rapid-covid19@nsf.gov.

• Complete guidance on submitting a RAPID proposal may be found in Chapter II.E.1 of the [NSF Proposal and Award Policies and Procedures Guide](https://www.nsf.gov).